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Association of ATP6V1B2 rs1106634 with lifetime risk of
depression and hippocampal neurocognitive deﬁcits: possible
novel mechanisms in the etiopathology of depression
X Gonda1,2,3, N Eszlari2,3, IM Anderson4,5, JFW Deakin4,5,6, G Bagdy2,3 and G Juhasz2,3,4,5,7
Current understanding and treatment of depression is limited to the monoaminergic theory with little knowledge of the
involvement of other cellular processes. Genome-wide association studies, however, implicate several novel single-nucleotide
polymorphisms with weak but replicable effects and unclariﬁed mechanisms. We investigated the effect of rs1106634 of the
ATPV1B2 gene encoding the vacuolar H+ATPase on lifetime and current depression and the possible mediating role of neuroticism
by logistic and linear regression in a white European general sample of 2226 subjects. Association of rs1106634 with performance
on frontal (Stockings of Cambridge (SOC)) and hippocampal-dependent (paired associates learning (PAL)) cognitive tasks was
investigated in multivariate general linear models in a smaller subsample. The ATP6V1B2 rs1106634 A allele had a signiﬁcant effect
on lifetime but not on current depression. The effect of the A allele on lifetime depression was not mediated by neuroticism. The A
allele inﬂuenced performance on the PAL but not on the SOC test. We conclude that the effects of variation in the vacuolar ATPase
may point to a new molecular mechanism that inﬂuences the long-term development of depression. This mechanism may involve
dysfunction speciﬁcally in hippocampal circuitry and cognitive impairment that characterizes recurrent and chronic depression.
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INTRODUCTION
Major depression has a great burden both in terms of suffering
and costs for the society.1–5 However, its pathology is still unclear.
There is a strong genetic background with risk of ﬁrst-degree
relatives showing a 2.8-fold increase6–8 and twin studies suggest-
ing a 37–43% heritability.7
Due to its exceptionally large clinical heterogeneity, depression
is difﬁcult to study from a genetic point of view.6 Candidate gene
studies select polymorphisms based on linkage studies or
hypothetical choices concerning already known etiological
mechanisms in the neurobiology of depression. Therefore the
scope of investigated polymorphisms is rather narrow in terms of
the systems in question.9 Consistently replicated ﬁndings from
these studies are few and the identiﬁed polymorphisms confer a
small amount of risk. In contrast to association studies limited to
previous knowledge and researcher preferences, GWAS-s (gen-
ome-wide association studies) are more comprehensive and less
biased. However, as a major drawback genome-wide signiﬁcance
needs to be set to very low due to the large amount of hypothesis
testing. Furthermore, polymorphisms implicated in GWAS studies
with at least a suggestive signiﬁcance often show no connection to
mechanisms already implicated in the background of depression.6
Although one novel study using a very large cohort but less
intensive phenotyping based on self-reported depression identi-
ﬁed 15 genetic loci,10 generally no associations with a genome-
wide signiﬁcance are identiﬁed in individual studies in psychiatric
patients. A recent meta-analysis of three GWAS-s in major
depressive disorder observed the strongest associations for three
intronic single-nucleotide polymorphisms (SNPs), including one
(rs1106634) in the ATP6V1B2 gene (Figure 1) encoding the B
subunit of the vacuolar H+ pump-ATPase with a suggestive
signiﬁcance (P= 6.78 × 107) for the A allele.11 In another large
meta-analysis in schizophrenia and bipolar disorder, rs1106634
also exhibited a suggestive P-value (3.97 × 10− 6) although for the
opposite, T allele.12 The cytosolic domain where this subunit is
located is part of a transmembrane complex playing a role in the
generation of H+ gradients across synaptic vesicle membranes
and is a key player in receptor-mediated endocytosis.11
With our current understanding and treatment approaches in
depression mainly conﬁned to monoaminergic theory and far less
than adequate due to limited efﬁcacy and signiﬁcant side effects,
it would be valuable to investigate SNPs with a weak but
replicable effect in GWAS-s to identify new molecules of
vulnerability, mechanisms of etiopathology and targets of
treatment. In our study, we investigated the association of
rs1106634 and depression-related phenotypes including lifetime
and current depression as well as hippocampal and prefrontal-
related neurocognitive deﬁcits in a large, general, nonclinical
sample in Manchester and Budapest.
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MATERIALS AND METHODS
This present research is part of the NewMood study, funded by the
European Union (New Molecules in Mood Disorders, Sixth Framework
Program of the EU, LSHM-CT-2004-503474), carried out in accordance with
the Declaration of Helsinki, and approved by the local Ethics Committees
(Scientiﬁc and Research Ethics Committee of the Medical Research Council,
Budapest, Hungary; and North Manchester Local Research Ethics
Committee, Manchester, UK).
Participants
All participants provided written informed consent. Our study involved two
levels, 1 and 2. Level 1 sample was recruited through advertisements and
general practices in Budapest, and through advertisements, general
practices and a website in Greater Manchester. N= 2226 subjects
(n=904 in Budapest and n= 1322 in Manchester) were successfully
genotyped for ATP6V1B2 rs1106634, and provided information about
gender, age, lifetime and current depression by ﬁlling out the NewMood
questionnaire pack.13 All Level 1 subjects were of white European ethnic
origin, and had no relatives participating.
Level 2 sample was collected in Manchester. N= 206 subjects (n= 114
having participated in Level 1; and n=92 new subjects recruited through
advertisements) were successfully genotyped for ATP6V1B2 rs1106634 and
interviewed for Montgomery-Åsberg Depression Rating Scale and lifetime
depression, provided information about gender, age and neuroticism, and
carried out both cognitive tasks.
Phenotypic assessment
Level 1 questionnaire pack included the Brief Symptom Inventory (BSI),14
the Big Five Inventory (BFI-44)15 and a background questionnaire
containing a question about lifetime depression, validated with face-to-
face diagnostic interviews in a subsample.13 We calculated a continuous
weighted score (sum of item scores divided by the number of items
completed) for the BSI depression subscale (depression items plus
additional items) (BSI-Dep), and for the BFI-44 neuroticism scale and used
these variables for the analyses.
In Level 2, we measured lifetime depression with a clinical diagnosis of
major depressive disorder: trained researchers administered the Structured
Clinical Interview for DSM-IV (SCID-I/NP).16 Those with bipolar disorder or
any other psychiatric condition except for major depression were excluded
from the analyses. Montgomery-Åsberg Depression Rating Scale (MADRS)
was used to measure depressive symptoms.17 Neuroticism was measured
with the neuroticism subscale of the NEO-PI-R.18
In Level 2, to assess neurocognitive endophenotypes of depression, we
chose two computerized tasks from the Cambridge Neuropsychological
Test Automated Battery software (CANTAB; http://www.cambridgecogni
tion.com/). Paired associates learning (PAL) task assesses episodic memory,
Figure 1. Linkage disequilibrium (LD) values (R2) and haplotype blocks of single-nucleotide polymorphisms (SNPs) in and around the
ATP6V1B2 gene. The information is based on the CEU population of version 2 and release 24 of the HapMap project (http://hapmap.ncbi.nlm.
nih.gov/).
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thus medial temporal lobe functioning, by requiring the subject to learn
paired associations between a visual pattern and a spatial location (http://
www.cambridgecognition.com/tests/paired-associates-learning-pal), and
indicated a hippocampal dysfunction in depression19 and other neurop-
sychiatric disorders.20,21 Three scores were calculated and used in our
analyses: memory score on the ﬁrst trial (PAL memory score), total number
of errors (PAL errors) and total number of trials (PAL required trials). The
other task, Stockings of Cambridge (SOC) measures frontal lobe function
by a test of spatial planning and spatial working memory (http://www.
cambridgecognition.com/tests/stockings-of-cambridge-soc), and is sensi-
tive to executive deﬁcits in depression.19,22 We calculated and analyzed
two scores of SOC: mean of all initial thinking times throughout the SOC
task (SOC ITT), and rate of problems solved in minimum moves (SOC
correct trial rate).
Genotyping
Participants provided buccal mucosa cells using a genetic saliva sampling
kit. We extracted genomic DNA according to Freeman et al.23 ATP6V1B2
rs1106634 was genotyped with Sequenom MassARRAY technology
(Sequenom, San Diego, CA, USA www.sequenom.com). All laboratory work
was performed under ISO9001:2000 quality management requirements,
and blinded for phenotype.
Statistical analyses
We used PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) to
calculate Hardy–Weinberg equilibrium and to build regression models in
Level 1. Logistic regression equations were run on lifetime depression, and
linear regressions on BSI depression score, in additive, dominant and
recessive models, with ATP6V1B2 rs1106634, population (Budapest or
Manchester), gender and age as predictors. Bonferroni-corrected signiﬁ-
cance threshold was P⩽ 0.0083 for these six analyses. As post hoc tests in
Level 1, with a nominal P⩽ 0.05 signiﬁcance threshold, we intended to
replicate the signiﬁcant ﬁndings in the Budapest and Manchester
subsamples, separately. Also as post hoc tests we tested the putative
mediating effect of neuroticism in the combined Level 1 Budapest
+Manchester sample for the signiﬁcant ﬁndings, including it as an
additional predictor in the regression equations.
IBM SPSS Statistics 23 was used for descriptive statistics, and to test post
hoc effect of ATP6V1B2 rs1106634 on PAL and SOC performance in Level 2.
We built a multivariate general linear model for the three PAL outcomes,
and another one for the two SOC outcomes, with ATP6V1B2 rs1106634 as a
ﬁxed factor and gender, age, lifetime depression, MADRS score and NEO-
PI-R neuroticism score as covariates in both models. A nominal P⩽ 0.05
signiﬁcance threshold was applied. Similar multivariate models, but
without rs1106634, were used to gain residuals for the task performance
variables in order to visualize the genetic effect on them in the ﬁgures.
Quanto (http://biostats.usc.edu/Quanto.html) was used to calculate the
power of the main six tests, giving the Bonferroni-corrected P⩽ 0.0083 as
type I error rate. Power to detect main genetic effects on lifetime
depression is moderate or low: assuming an odds ratio (OR) of 1.2 and a
population prevalence of 15% for lifetime depression, the power in our
sample is 50.31% in a log-additive, 29.98% in a dominant and 5.79% in a
recessive model. The power is high to detect genetic main effects on BSI
depression score (of which mean is 0.87 and s.d. is 0.931 in our sample and
n= 2222, assuming an R2 = 1%): the power is 98.15% in all three models.
Individually written R-scripts24 were applied in the PLINK analysis of the
Level 1 subsamples to perform the separate analyses in the Budapest and
Manchester subsamples.
RESULTS
Description of the sample
Rs1106634 A is the minor allele in our sample. Our sample was in
Hardy–Weinberg equilibrium (P40.05). Description of the Level 1
and 2 samples is shown in Table 1. The Level 1 Budapest and
Manchester subsamples differ signiﬁcantly in all variables except
for gender, so including population as a predictor in the
regression equations is required. T
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Effect of the A allele on lifetime and current depression
In the combined Level 1 sample, ATP6V1B2 rs1106634 A allele
exerts a Bonferroni-corrected signiﬁcant effect as a risk for lifetime
depression in additive and dominant, but not in recessive models
(Table 2). Nevertheless, its effect is not signiﬁcant on BSI
depression score in any of the models (Table 2). Post hoc analyses
indicated that the risk of the A allele on lifetime depression is
replicable in the two subsamples (Table 3).
The mediatory role of neuroticism
We investigated whether the effect of ATP6V1B2 rs1106634 A
allele on lifetime depression is due to the association of the A
allele with higher neuroticism scores. In the combined Level 1
sample, with population, gender and age as covariates, A allele is
in a signiﬁcant positive association with neuroticism score (its
β= 0.102; t= 2.724; P= 0.006 in an additive, and β= 0.114; t= 2.721;
P= 0.007 in a dominant model). Lifetime depression also
associates positively to neuroticism (t=− 27.996; Po0.001): mean
neuroticism score is 3.70 ± 0.026 in those who did, and
2.75 ± 0.022 in those who did not report lifetime depression. So,
we could test the possible mediating role of neuroticism in the
effect of the A allele on lifetime depression risk. As post hoc tests
with a nominal P⩽ 0.05 signiﬁcance threshold, including neuroti-
cism as an additional covariate in the regression equations,
besides population, gender and age, the signiﬁcant positive effect
of A allele on lifetime depression risk decreased but did not
disappear: OR = 1.317; t= 2.562; P= 0.010 in the additive, and
OR= 1.367; t= 2.622; P= 0.009 in the dominant model (for
comparisons, see Table 2), indicating that the effect of the A
allele on depression is not mediated solely by the association of
this allele with neuroticism.
Association of the A allele with brain region-speciﬁc cognitive
performance
Next, we tested post hoc, in Level 2, if ATP6V1B2 rs1106634 A allele
explains the variance of performance on the two neurocognitive
tasks independently of the variance explained by lifetime
depression, current depression and neuroticism. A multivariate
general linear model was built with A allele as a ﬁxed factor (in a
dominant model, because of low number in the AA group, see
Table 1), gender, age, lifetime depression, MADRS and neuroticism
as covariates, and PAL memory score, PAL errors and PAL required
trials as the dependent variables. Wilks’ Lambda of the A allele
showed F= 5.661, P= 0.001. The A allele exerted a nominally
signiﬁcant effect on each PAL variable in the model (PAL memory:
F= 15.159; Po0.001; PAL errors: F= 9.350; P= 0.003; PAL required
trials: F= 8.546; P= 0.004). Another multivariate general linear
model was built with the A allele as a ﬁxed factor (in a dominant
model), gender, age, lifetime depression, current depression
(MADRS) and neuroticism as covariates, and SOC ITT and SOC
correct trial rate as dependent variables. For Wilks’ Lambda of the
A allele, F= 1.665; P= 0.192. In this model, the A allele did not exert
a signiﬁcant effect on any of the SOC variables (SOC ITT: F= 0.612;
P= 0.435; SOC correct trial rate: F= 2.039; P= 0.155; Figure 2).
DISCUSSION
In our study in a large general sample ATP6V1B2 rs1106634 A allele
was a signiﬁcant risk factor for lifetime major depression but was
not associated with current depressive symptom manifestation.
This risk effect of the A allele on depression was only partially
mediated by neuroticism, a well-known risk factor for depression,
which was associated with both depression and the A allele in our
study indicating overlapping genetic risk but different mechan-
isms. Furthermore, our results show that rs1106634 may exert a
brain region-speciﬁc effect independently of lifetime history or
current level of depression impacting temporal-hippocampal but
not frontal functions as reﬂected by signiﬁcantly decreased
performance in A allele carriers on the PAL but not on the SOC
neurocognitive test. Our results thus show that ATP6V1B2
rs1106634 may play an important role in the long-term develop-
ment and risk for depression, but not in its cross-sectional
symptomatology, possibly via its effect on hippocampal function
conceived to play a central role in depression.
Table 2. Main effect of ATP6V1B2 rs1106634 on the two depression phenotypes in our Level 1 sample (Manchester and Budapest combined sample)
Lifetime depression BSI depression score
Model N OR 95% CI t P-values N β s.e. t P-values
Additive 2226 1.406 1.165–1.696 3.560 o0.001 2222 0.048 0.039 1.214 0.225
Dominant 2226 1.465 1.189–1.804 3.591 o0.001 2222 0.042 0.044 0.965 0.335
Recessive 2226 1.527 0.779–2.993 1.234 0.217 2222 0.179 0.142 1.255 0.210
Abbreviations: 95% CI, 95% conﬁdence interval of OR; BSI, Brief Symptom Inventory; OR, odds ratio; P, nominal P-value; s.e., standard error of β. Population
(Budapest or Manchester), gender and age were covariates in all of the six regression equations. The three models correspond to that A is the minor allele in all
cases. Signiﬁcant ﬁndings according to the Bonferroni-corrected threshold (P⩽ 0.0083) are marked with bold.
Table 3. Main effect of ATP6V1B2 rs1106634 on lifetime depression in the two Level 1 subsamples in Manchester and Budapest
Budapest Manchester
Model N OR 95% CI t P-values N OR 95% CI t P-values
Additive 904 1.541 1.109–2.142 2.574 0.010 1322 1.342 1.070–1.682 2.549 0.011
Dominant 904 1.628 1.129–2.348 2.609 0.009 1322 1.387 1.079–1.784 2.549 0.011
Abbreviations: 95% CI, 95% conﬁdence interval of OR; OR, odds ratio; P, nominal P-value. Gender and age were covariates in all of the four regression
equations. The models correspond to that A is the minor allele in both subsamples. All ﬁndings are nominally signiﬁcant (P⩽ 0.05).
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Association of rs1106634 A allele with risk for lifetime depression
but not current depressive symptoms
In line with previous GWAS-s implicating the involvement of the
ATP6V1B2 rs1106634 in affective disorders,11,12,25 we found a
signiﬁcant association between the A allele and lifetime depres-
sion in our large, average population of 2226 subjects and
replicated our ﬁndings in two independent subsamples from
Budapest and Manchester showing the involvement of this variant
in the lifetime risk for depression. Interestingly, we found no
association between this polymorphism and current depressive
symptoms, indicating that this genetic variant is not associated
directly with currently detectable symptoms but may be related to
cellular mechanisms associated with the development of depres-
sion on brain functional or structural levels. On the basis of our
ﬁndings, rs1106634 is involved in the development of a trait-like
risk for depression rather than its state-like manifestation.
Furthermore, it is possible that consequences of the presence of
A allele are manifested in neurocognitive rather than mood
symptoms of depression which are hypothesized to play a central
role in depression but are not captured by conventional rating
scales, and can be only detected by assessing neurocognitive
performance, as indicated in our study by the signiﬁcantly lower
performance on the PAL test reﬂecting impaired hippocampal
function in A allele carriers.
Association of rs1106634 with lifetime risk of depression is not
mediated by neuroticism
The rs1106634 A allele was signiﬁcantly associated with neuroti-
cism, a well-established prospective risk factor for depression.26
Neuroticism is a personality trait of negative emotionality
associated with less adaptive coping with inner and outer
stressors and increased mood lability leading to a heightened
risk of experiencing anxiety and depressed mood.27 Therefore, its
presence is likely to play a developmental role in depression,
which further supports our notion that the A allele inﬂuences
long-term adjustment and trait-like risk factors rather than state-
like symptomatic presentation of depression. Although neuroti-
cism is one of the most widely studied endophenotypes of
depression with about 55% of shared genetic risk,28 we found that
neuroticism only partially mediated the effects of rs1106634 on
lifetime depression. We conclude that rs1106634 may inﬂuence
neuroticism and depression in ways that are partially
independent.
Association of rs1106634 with hippocampal but not prefrontal
neurocognitive dysfunction
In our study, rs1106634 A allele was associated with hippocampal
cognitive deﬁcits indicated by decreased performance on all
measures of the PAL task independently of lifetime or current
depression and neuroticism, while prefrontal functions indicated
by the SOC test remained intact. Thus our results raise the
possibility that the effect of this polymorphism is area-speciﬁc
affecting temporal rather than prefrontal lobe function. Given the
role of the vacuolar ATPase in cellular function and the fact that
the hippocampus is an area with high energy and oxygen need
and increased vulnerability compared with other regions,29–31 it is
possible that this area is more sensitive to possible functional
consequences of this polymorphic variant.
PAL performance involves learning random visuospatial asso-
ciations and is sensitive to hippocampal damage.21 Michopoulos
et al. reported that impaired PAL was associated with measures of
the severity and chronicity of depression including illness duration
and number of prior episodes. In contrast in the same study no
such measures of depression chronicity were found to be
associated with SOC scores.19 This is in line with our assumption
that rs1106634 effects are reﬂected in lifetime rather than acute
depression measures and are linked to long-term risk and
development of depression.
Our results indicating a speciﬁc association between hippo-
campal dysfunction and rs1106634 are especially interesting as
hippocampal dysfunction is thought to play a central role as part
of a larger dysregulated circuitry implicated in the pathophysiol-
ogy of depression.32,33 Loss of hippocampal volume is associated
with several measures of increased long-term depression severity
and worse clinical outcome33 and structural effects of genetic
inﬂuences.34 The hippocampus is considered a brain region with
increased sensitivity to stress35 resulting in structural changes as
well as enhanced vulnerability to metabolic insults33 and
depression is also a highly stress-associated illness. Therefore,
the possible consequences of genetically determined differences
in vacuolar H+ATPase may be especially manifested in the most
Figure 2. Multivariate general linear models indicate a signiﬁcant
effect of ATP6V1B2 rs1106634 genotype on PAL task performance
but not on SOC task performance. Multivariate general linear
models for the three PAL variables (a) and the two SOC variables (b)
with gender, age and lifetime depression, current (MADRS)
depression and neuroticism as covariates. Means of standardized
residuals for the PAL (a) and SOC (b) variables are displayed in
function of ATP6V1B2 rs1106634 genotype. A allele carriers show a
signiﬁcantly lower memory score on the ﬁrst trial (Po0.001), but a
signiﬁcantly higher total number of errors (P= 0.003) and required
trials (P= 0.004) than those with GG genotype in the PAL task (a).
However, the two genotype groups (A allele carriers and GG carriers)
do not differ in the two aspects of SOC performance (SOC ITT
P= 0.435, SOC correct trial rate P= 0.155) (b). PAL, paired associates
learning task; PAL errors, total number of errors on PAL; PAL memory
score, memory score on the ﬁrst trial of PAL; PAL required trials, total
number of trials on PAL; SOC, Stockings of Cambridge task; SOC
correct trial rate, rate of problems solved in minimum moves; SOC
ITT, mean of all initial thinking times throughout the SOC task.
Means (and the s.e.m.) of standardized residuals for the three PAL (a)
and the two SOC (b) scores, partialling out variance accounted for
by gender, age, lifetime depression, MADRS and neuroticism, are
represented according to genotype.
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vulnerable regions such as the hippocampus in high stress-
associated illnesses such as depression.
Possible mechanisms behind the role of rs1106634 in depression
and hippocampal dysfunction
Rs1106634 is located in the intron of the ATP6V1B2 gene,
encoding the B subunit of the ATP-catalytic site containing the
V1 cytosolic domain of the vacuolar proton pump-ATPase,11 which
mediates acidiﬁcation of various eukaryotic intracellular organelles
such as lysosomes and endosomes, necessary for processes
including protein sorting, receptor-mediated endocytosis and
synaptic vesicle proton-gradient generation. The protonmotive
force generated by vacuolar ATPases is used for various secondary
reactions including synaptic vesicular reuptake, accumulation and
storage.36,37 Transport including retrieval and reemployment of
synaptic vesicles is an essential component in the management
and maintenance of neurotransmission. The vacuolar H+ATPase
plays a key role in the energization of regenerated synaptic
vesicles after endocytosis, and thus in providing power for the
replenishment of neurotransmitters via speciﬁc vesicular
transporters.37,38 Therefore generation of the electrochemical H+
gradient is essential and even its minor or partial disturbance may
cause altered quantal neurotransmitter release.38,39 Vacuolar
ATPase inhibition was found to cause downregulation in
important signaling pathways including Wnt and Notch, although
it has not yet been clariﬁed to what extent this effect is a
consequence of its function in endosome acidiﬁcation or whether
it is due to its effect on endocytosis and trafﬁcking.40 Vacuolar
ATPase was also found to maintain neural stem cells in the
developing cortex of mice.40 Although the role of vacuolar ATPase
in central nervous system function is becoming clearer, no speciﬁc
effect of this polymorphism on neuronal function has been
speciﬁcally investigated.
One possible mechanism by which variations in the vacuolar
ATPase may exert their effect on depression risk is its role in
oxidative stress, also implicated in the etiopathology of depres-
sion. Emotional stressors appear to induce inﬂammatory
responses which are in turn associated with increased proin-
ﬂammatory cytokine production, stimulating reactive oxygen and
nitrogen species production and leading to oxidative and
nitrosative stress, free radical production and brain damage by
increasing neurodegeneration and impairing neurogenesis.41
Chronic inﬂammation as well as oxidative and nitrosative stress
has long been hypothesized to play a role in recurrent major
depression and especially in neurocognitive deﬁcits.31,41 Cellular
redox status may play a role in the regulation of the vacuolar H
+ATPase hypothesized to be a redox sensor regulating neuro-
transmitter storage in response to growth factor signaling or
oxidative stress, leading to decreased neurotransmitter amounts
in vesicles and therefore decreased or diminished neurotransmit-
ter release.42 In a more recent GWAS, a suggestive association
between serum myeloperoxidase levels and a region on chromo-
some 8p21.3 containing ATP6V1B2 genes was reported.43 Myelo-
peroxidase is a surrogate marker of prooxidative stress in major
depression, and its serum levels were previously associated with
depression.44 Myeloperoxidase expression was also reported to be
associated with neurodegeneration, higher risk of Alzheimer’s
disease,45 neuronal cell death and neurogenesis inhibition.41
The brain shows enhanced vulnerability to oxidative damage as
it uses large amounts of oxygen. Lipids, including unsaturated
fatty acids, which are especially reactible with free radicals are
abundant in central nervous system cells. Furthermore, several
brain regions are high in metal ions that promote reactive oxygen
species formation, and lower antioxidant concentrations are
observable in the brain compared with other body organs.41
The most sensitive to oxidative damage in the central nervous
system are, among others, CA1 and CA4 hippocampal regions as
well as the dorsal lateral striatum and III and V cortex layers.31
Especially CA1 neurons are highly vulnerable, playing a role in
long-term memory and spatially related tasks,30 which corre-
sponds to the deﬁcit seen in our study.
In silico functional analysis of rs1106634 and comparison with
results of the Psychiatric Genetic Consortium GWAS
In silico functional prediction using the SNP Function Prediction
Tool (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm) showed
no functional effects of our investigated SNP rs1106634, however,
a nearby SNP with an LD of 0.62, namely the rs1042426, is a
microRNA binding site, which suggests that this genetic region
may have functional consequences related to gene expression
regulation. Furthermore, the latest mega-analysis of the Psychia-
tric Genetic Consortium demonstrated that SNPs in high LD
(based on the CEU population data) with rs1106634, namely
rs6586899 (r2 = 0.96) and rs4335136 (r2 = 0.86), showed nominally
signiﬁcant associations with major depressive disorder (rs6586899
P= 0.004, rs4335136 P= 0.017), while the functional rs1042426 has
a trend effect (P= 0.089) supporting the weak but replicable role
of ATP6V1B2 in lifetime depression.46
Limitations
Several limitations of our study must be noted. We measured
depressive symptoms and neurocognitive performance cross-
sectionally. Both current and lifetime depression was based on
self-report thus could be inﬂuenced by reporting and recalling
bias. Recent life events possibly inﬂuencing current depression as
well as general intellectual performance possibly impacting
neurocognitive performance were not included in our models.
Furthermore, our study sample is a general, non-epidemiological
and non-representative population sample based on volunteers,
therefore may be subject to sampling bias especially with respect
to depression.
Conclusion and implication for further studies
The main ﬁnding of our study is supporting the role of the
ATP6V1B2 rs1106634 A allele, implicated in depression GWAS-s
with a suggestive signiﬁcance, as a risk allele for lifetime but not
current depression suggesting a role in the long-term develop-
ment of affective illness. This ﬁnding is further underlined by the
association of this SNP with neuroticism, a well-established risk
factor of depression, while the fact that neuroticism only partially
mediated the association between rs1106634 and depression
indicates a differential involvement of rs1106634 in these two
phenomena. Our results also show that the effect of rs1106634 on
lifetime risk of depression may be due to the association of the A
allele with hippocampal dysfunction, thought to play a central role
in the development of depression. We must also mention that
while rs1106634 was implicated in several GWAS-s in psychiatric
patients, it was not among the 15 genetic loci identiﬁed in major
depression in a most recent study using an extremely large cohort
with less intensive phenotyping approach using self-reported
lifetime depression,10 the same phenotype as used in our study.
On the clinical level, our ﬁndings concerning the role of the
vacuolar ATPase in depression and depression-associated cogni-
tive deﬁcits suggest that pharmacological interventions targeting
this molecule may be promising new molecular agents in the
treatment of depression in general and also in cases with more
marked neurocognitive symptoms, also possibly able to tackle the
progressive and degenerative nature of such symptoms. Our
results thus emphasize the importance of looking beyond the
monoaminergic systems in investigating mechanisms underlying
depression in order to establish a more accurate model of this
illness and pinpoint possible targets for pharmacological inter-
vention, and also stress the importance of investigating
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polymorphisms implicated in depression GWAS-s, even if only
with a weak effect, with respect to their possible role and
mechanism.
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